Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2013

Open Access 01-12-2013 | Research article

Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction

Authors: Heidi M Christensen, Morten Schou, Jens P Goetze, Jens Faber, Jan Frystyk, Allan Flyvbjerg, Caroline Kistorp

Published in: BMC Cardiovascular Disorders | Issue 1/2013

Login to get access

Abstract

Background

Low body mass index (BMI) is associated with a poor outcome in chronic heart failure (CHF). An inverse association between BMI and adiponectin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been reported. The aim of the present study was to investigate whether novel markers of neurohormonal activation, inflammation, and endothelial dysfunction are associated with BMI in CHF.

Methods

In a cross-sectional study including 171 patients with CHF and a left ventricular ejection fraction (LVEF) ≤45% the impact of BMI on circulating plasma concentrations of adiponectin, α-defensins, high sensitivity C-reactive protein (hsCRP), copeptin, mid-regional pro-adrenomedullin (MR-proADM), NT-proBNP, and mid-regional pro-A-type natriuretic peptide (MR-proANP) were evaluated.

Results

In multivariable linear regression analysis including age, sex, LVEF, New York Heart Association functional classification (NYHA), estimated glomerular filtration rate (eGFR), and diabetes, only NT-proBNP (β = −0.32) and adiponectin (β = −0.39) remained independently associated with BMI. MR-proANP was associated with BMI but adjusting for age attenuated the relation being no longer significant.

Conclusions

Among biomarkers typically increased in patients with CHF only adiponectin and NT-proBNP demonstrated independent inverse associations with BMI. This indicates a direct effect of these two biomarkers enhancing the wasting process seen in CHF.
Appendix
Available only for authorised users
Literature
1.
go back to reference Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al: Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997, 349: 1050-1053. 10.1016/S0140-6736(96)07015-8.CrossRefPubMed Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al: Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997, 349: 1050-1053. 10.1016/S0140-6736(96)07015-8.CrossRefPubMed
2.
go back to reference Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA: Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008, 156: 13-22. 10.1016/j.ahj.2008.02.014.CrossRefPubMed Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA: Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008, 156: 13-22. 10.1016/j.ahj.2008.02.014.CrossRefPubMed
3.
go back to reference Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, et al: Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012, 122: 1022-1036. 10.1172/JCI59701.CrossRefPubMedPubMedCentral Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, et al: Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012, 122: 1022-1036. 10.1172/JCI59701.CrossRefPubMedPubMedCentral
4.
go back to reference Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al: Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006, 52: 1528-1538. 10.1373/clinchem.2006.069575.CrossRefPubMed Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al: Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006, 52: 1528-1538. 10.1373/clinchem.2006.069575.CrossRefPubMed
5.
go back to reference Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, et al: Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine. 2012, 43: 626-634.CrossRefPubMed Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, et al: Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine. 2012, 43: 626-634.CrossRefPubMed
6.
go back to reference Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005, 112: 1756-1762. 10.1161/CIRCULATIONAHA.104.530972.CrossRefPubMed Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005, 112: 1756-1762. 10.1161/CIRCULATIONAHA.104.530972.CrossRefPubMed
7.
go back to reference McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, et al: Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J. 2007, 28: 829-835. 10.1093/eurheartj/ehm033.CrossRefPubMed McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, et al: Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J. 2007, 28: 829-835. 10.1093/eurheartj/ehm033.CrossRefPubMed
8.
go back to reference Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, et al: Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail. 2012, 14: 22-31. 10.1093/eurjhf/hfr157.CrossRefPubMed Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, et al: Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail. 2012, 14: 22-31. 10.1093/eurjhf/hfr157.CrossRefPubMed
9.
go back to reference von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, et al: Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol. 2007, 50: 1973-1980. 10.1016/j.jacc.2007.08.012.CrossRefPubMed von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, et al: Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol. 2007, 50: 1973-1980. 10.1016/j.jacc.2007.08.012.CrossRefPubMed
10.
go back to reference George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al: Circulating adiponectin concentrations in patients with congestive heart failure. Heart. 2006, 92: 1420-1424. 10.1136/hrt.2005.083345.CrossRefPubMedPubMedCentral George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al: Circulating adiponectin concentrations in patients with congestive heart failure. Heart. 2006, 92: 1420-1424. 10.1136/hrt.2005.083345.CrossRefPubMedPubMedCentral
11.
go back to reference Turer AT, Khera A, Ayers CR, Turer CB, Grundy SM, Vega GL, et al: Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia. 2011, 54: 2515-2524. 10.1007/s00125-011-2252-z.CrossRefPubMedPubMedCentral Turer AT, Khera A, Ayers CR, Turer CB, Grundy SM, Vega GL, et al: Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia. 2011, 54: 2515-2524. 10.1007/s00125-011-2252-z.CrossRefPubMedPubMedCentral
12.
go back to reference Araujo JP, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P: Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail. 2009, 11: 567-572. 10.1093/eurjhf/hfp046.CrossRefPubMed Araujo JP, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P: Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail. 2009, 11: 567-572. 10.1093/eurjhf/hfp046.CrossRefPubMed
13.
go back to reference von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, et al: Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010, 12: 484-491. 10.1093/eurjhf/hfq031.CrossRefPubMed von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, et al: Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010, 12: 484-491. 10.1093/eurjhf/hfq031.CrossRefPubMed
14.
go back to reference Vila G, Riedl M, Maier C, Struck J, Morgenthaler NG, Handisurya A, et al: Plasma MR-proADM correlates to BMI and decreases in relation to leptin after gastric bypass surgery. Obesity (Silver Spring). 2009, 17: 1184-1188. Vila G, Riedl M, Maier C, Struck J, Morgenthaler NG, Handisurya A, et al: Plasma MR-proADM correlates to BMI and decreases in relation to leptin after gastric bypass surgery. Obesity (Silver Spring). 2009, 17: 1184-1188.
15.
go back to reference Morawiec B, Kawecki D: Copeptin: a new marker in cardiology. J Cardiovasc Med (Hagerstown ). 2013, 14: 19-25. 10.2459/JCM.0b013e3283590d59.CrossRef Morawiec B, Kawecki D: Copeptin: a new marker in cardiology. J Cardiovasc Med (Hagerstown ). 2013, 14: 19-25. 10.2459/JCM.0b013e3283590d59.CrossRef
16.
go back to reference McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al: Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009, 120: 2188-2196. 10.1161/CIRCULATIONAHA.109.849117.CrossRefPubMed McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al: Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009, 120: 2188-2196. 10.1161/CIRCULATIONAHA.109.849117.CrossRefPubMed
17.
go back to reference Rawson ES, Freedson PS, Osganian SK, Matthews CE, Reed G, Ockene IS: Body mass index, but not physical activity, is associated with C-reactive protein. Med Sci Sports Exerc. 2003, 35: 1160-1166. 10.1249/01.MSS.0000074565.79230.AB.CrossRefPubMed Rawson ES, Freedson PS, Osganian SK, Matthews CE, Reed G, Ockene IS: Body mass index, but not physical activity, is associated with C-reactive protein. Med Sci Sports Exerc. 2003, 35: 1160-1166. 10.1249/01.MSS.0000074565.79230.AB.CrossRefPubMed
18.
go back to reference Christensen HM, Frystyk J, Faber J, Schou M, Flyvbjerg A, Hildebrandt P, et al: alpha-Defensins and outcome in patients with chronic heart failure. Eur J Heart Fail. 2012, 14: 387-394. 10.1093/eurjhf/hfs021.CrossRefPubMed Christensen HM, Frystyk J, Faber J, Schou M, Flyvbjerg A, Hildebrandt P, et al: alpha-Defensins and outcome in patients with chronic heart failure. Eur J Heart Fail. 2012, 14: 387-394. 10.1093/eurjhf/hfs021.CrossRefPubMed
19.
go back to reference Galatius S, Gustafsson F, Nielsen PH, Atar D, Hildebrandt PR: An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area. Am Heart J. 2002, 144: E2-10.1067/mhj.2002.123841.CrossRefPubMed Galatius S, Gustafsson F, Nielsen PH, Atar D, Hildebrandt PR: An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area. Am Heart J. 2002, 144: E2-10.1067/mhj.2002.123841.CrossRefPubMed
20.
go back to reference Joseph G, Tarnow L, Astrup AS, Hansen TK, Parving HH, Flyvbjerg A, et al: Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. J Clin Endocrinol Metab. 2008, 93: 1470-1475. 10.1210/jc.2007-1910.CrossRefPubMed Joseph G, Tarnow L, Astrup AS, Hansen TK, Parving HH, Flyvbjerg A, et al: Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. J Clin Endocrinol Metab. 2008, 93: 1470-1475. 10.1210/jc.2007-1910.CrossRefPubMed
21.
go back to reference Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, et al: Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl. 1999, 230: 177-181.CrossRefPubMed Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, et al: Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl. 1999, 230: 177-181.CrossRefPubMed
22.
go back to reference Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A: Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia. 2005, 48: 1911-1918. 10.1007/s00125-005-1850-z.CrossRefPubMed Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A: Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia. 2005, 48: 1911-1918. 10.1007/s00125-005-1850-z.CrossRefPubMed
23.
go back to reference Morgenthaler NG, Struck J, Thomas B, Bergmann A: Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004, 50: 234-236. 10.1373/clinchem.2003.021204.CrossRefPubMed Morgenthaler NG, Struck J, Thomas B, Bergmann A: Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004, 50: 234-236. 10.1373/clinchem.2003.021204.CrossRefPubMed
24.
go back to reference Morgenthaler NG, Struck J, Alonso C, Bergmann A: Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005, 51: 1823-1829. 10.1373/clinchem.2005.051110.CrossRefPubMed Morgenthaler NG, Struck J, Alonso C, Bergmann A: Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005, 51: 1823-1829. 10.1373/clinchem.2005.051110.CrossRefPubMed
25.
go back to reference Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006, 52: 112-119. 10.1373/clinchem.2005.060038.CrossRefPubMed Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006, 52: 112-119. 10.1373/clinchem.2005.060038.CrossRefPubMed
26.
go back to reference Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J: Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab. 2008, 19: 130-137. 10.1016/j.tem.2007.11.006.CrossRefPubMed Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J: Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab. 2008, 19: 130-137. 10.1016/j.tem.2007.11.006.CrossRefPubMed
27.
go back to reference Masson S, Gori F, Latini R, Milani V, Flyvbjerg A, Frystyk J, et al: Adiponectin in chronic heart failure: influence of diabetes and genetic variants. Eur J Clin Invest. 2011, 41: 1330-1338. 10.1111/j.1365-2362.2011.02548.x.CrossRefPubMed Masson S, Gori F, Latini R, Milani V, Flyvbjerg A, Frystyk J, et al: Adiponectin in chronic heart failure: influence of diabetes and genetic variants. Eur J Clin Invest. 2011, 41: 1330-1338. 10.1111/j.1365-2362.2011.02548.x.CrossRefPubMed
28.
go back to reference Bhandari SS, Davies JE, Struck J, Ng LL: Influence of confounding factors on plasma mid-regional pro-adrenomedullin and mid-regional pro-A-type natriuretic peptide concentrations in healthy individuals. Biomarkers. 2011, 16: 281-287. 10.3109/1354750X.2011.553750.CrossRefPubMed Bhandari SS, Davies JE, Struck J, Ng LL: Influence of confounding factors on plasma mid-regional pro-adrenomedullin and mid-regional pro-A-type natriuretic peptide concentrations in healthy individuals. Biomarkers. 2011, 16: 281-287. 10.3109/1354750X.2011.553750.CrossRefPubMed
29.
go back to reference Bartels ED, Nielsen JM, Bisgaard LS, Goetze JP, Nielsen LB: Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice1. Endocrinology. 2010, 151: 5218-5225. 10.1210/en.2010-0355.CrossRefPubMed Bartels ED, Nielsen JM, Bisgaard LS, Goetze JP, Nielsen LB: Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice1. Endocrinology. 2010, 151: 5218-5225. 10.1210/en.2010-0355.CrossRefPubMed
30.
go back to reference Birkenfeld AL, Boschmann M, Engeli S, Moro C, Arafat AM, Luft FC, et al: Atrial natriuretic peptide and adiponectin interactions in man 1. PLoS One. 2012, 7: e43238-10.1371/journal.pone.0043238.CrossRefPubMedPubMedCentral Birkenfeld AL, Boschmann M, Engeli S, Moro C, Arafat AM, Luft FC, et al: Atrial natriuretic peptide and adiponectin interactions in man 1. PLoS One. 2012, 7: e43238-10.1371/journal.pone.0043238.CrossRefPubMedPubMedCentral
31.
go back to reference Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice 2. Proc Natl Acad Sci U S A. 2001, 98: 2005-2010. 10.1073/pnas.98.4.2005.CrossRefPubMedPubMedCentral Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice 2. Proc Natl Acad Sci U S A. 2001, 98: 2005-2010. 10.1073/pnas.98.4.2005.CrossRefPubMedPubMedCentral
Metadata
Title
Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction
Authors
Heidi M Christensen
Morten Schou
Jens P Goetze
Jens Faber
Jan Frystyk
Allan Flyvbjerg
Caroline Kistorp
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2013
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/1471-2261-13-80

Other articles of this Issue 1/2013

BMC Cardiovascular Disorders 1/2013 Go to the issue